Betahistine mesylate
Based on 2 publication(s) in Google Scholar
Betahistine mesylate (OBE-101 mesylate) is an orally active histamine receptor modulator with blood-brain barrier permeability. Betahistine mesylate antagonizes presynaptic H3 receptors and weakly activates H1 receptors, thereby enhancing histamine/acetylcholine release and cholinergic neurotransmission. Betahistine mesylate inhibits pro-inflammatory cytokines, RORγt/Th17 differentiation, and type II collagen-specific lymph node cell proliferation. Betahistine mesylate promotes ERK1/2 and AKT phosphorylation, upregulates PPARγ, induces CTRP1/3/6/9/12, and produces histaminergic vasodilation; it also ameliorates vestibular dysfunction. Betahistine mesylate is used in research related to neurological disorders such as cognitive impairment and inflammatory diseases such as rheumatoid arthritis and otitis media.
For research use only. We do not sell to patients.
- Purity : 99.23%
- CAS No.: 54856-23-4
- Formula: C10H20N2O6S2
- Molecular Weight:328.41
-
Storage:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Biological Activity
Description
|
H1 Receptor |
H3 receptor |
IL-17A |
IL-6 |
TNF-α |
ERK1 |
ERK2 |
Akt |
PPAR-γ |
In Vitro
Betahistine mesylate inhibits the binding of [3H]Mepyramine in guinea pig cerebellar membranes with a Ki of 31 μM[5].
Betahistine mesylate is not an H3 autoreceptor agonist in rat brain cortex slices, but it antagonizes the inhibitory effect of exogenous histamine on [3H] histamine release, with a Ki of 6.9 μM[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Betahistine (10 mg/Kg; s.c.; for 15 consecutive days) mesylate ameliorates gentamicin-induced vestibular dysfunction in mice by inducing CTRP and activating ERK1/2-AKT/PPARγ, whereas inhibition of ERK and PPARγ blocks the behavioral benefits without altering CTRP induction[3].
Betahistine (10 mg/Kg; s.c.; for 15 consecutive days) mesylate improves vestibular behavioral dysfunction in Slc26a4loop/loop mutant mice and increases the levels of CTRP1, CTRP3, CTRP6, CTRP9, and CTRP12[3].
Betahistine (25-300 mg/kg; i.p.; single administration; 30 or 60 min before [3H]Mepyramine) mesylate reduces in vivo specific [3H]Mepyramine binding in the cerebral cortex of male albino mice only at high doses, with 300 mg/kg reducing binding to 32% of control at 30 min[5].
Betahistine (1-8 mg/mL; nasopharyngeal) mesylate improves eustachian tube function in rats, and this effect is independent of the H1 receptor and can be reproduced by the H3 agonist Ciproxifan (HY-14567)[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- Western Blot
- Naïve CD4+ T-cell subset differentiation/polarization
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Research Protocol for Inflammation-related Diseases
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
- Alzheimer’s Disease Modeling
- Kinase activity and phosphorylation assays
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Collagen-Induced Arthritis
- Ki-67 Immunostaining Proliferation Assay
- LPS-Induced Endotoxemia/Systemic Inflammation
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- Transepithelial/transendothelial electrical resistance assay
- Protocol for Kinase activity and phosphorylation assays
- MTT Cell Proliferation Assay
Chemical Information
-
CAS No. 54856-23-4
-
Appearance Solid
-
Molecular Weight 328.41
-
Formula C10H20N2O6S2
-
Color White to off-white
-
SMILES
CNCCC1=NC=CC=C1.CS(=O)(O)=O.CS(=O)(O)=O
-
Synonyms
OBE-101 mesylate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Pharm Res
Investigation of the Binding Characteristics of Agonists and Various Antagonists Targeting Histamine 1 Receptor. [Abstract]2025 Aug;42(8):1315-1329. PMID: 40760405 -
Brain Sci
Combination Lorcaserin and Betahistine Treatment Improves Cognitive Dysfunction and Dopaminergic Neuron Activity in a Rat Model of Diet-Induced Obesity. [Abstract]2025 Aug 25;15(9):913. PMID: 41008273
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (304.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0450 mL | 15.2249 mL | 30.4497 mL | 76.1244 mL |
| 5 mM | 0.6090 mL | 3.0450 mL | 6.0899 mL | 15.2249 mL | |
| 10 mM | 0.3045 mL | 1.5225 mL | 3.0450 mL | 7.6124 mL | |
| 15 mM | 0.2030 mL | 1.0150 mL | 2.0300 mL | 5.0750 mL | |
| 20 mM | 0.1522 mL | 0.7612 mL | 1.5225 mL | 3.8062 mL | |
| 25 mM | 0.1218 mL | 0.6090 mL | 1.2180 mL | 3.0450 mL | |
| 30 mM | 0.1015 mL | 0.5075 mL | 1.0150 mL | 2.5375 mL | |
| 40 mM | 0.0761 mL | 0.3806 mL | 0.7612 mL | 1.9031 mL | |
| 50 mM | 0.0609 mL | 0.3045 mL | 0.6090 mL | 1.5225 mL | |
| 60 mM | 0.0507 mL | 0.2537 mL | 0.5075 mL | 1.2687 mL | |
| 80 mM | 0.0381 mL | 0.1903 mL | 0.3806 mL | 0.9516 mL | |
| 100 mM | 0.0304 mL | 0.1522 mL | 0.3045 mL | 0.7612 mL |
Keywords
- Betahistine
- 54856-23-4
- OBE-101
- OBE101
- OBE 101
- Histamine Receptor
- Interleukin Related
- TNF Receptor
- ERK
- Akt
- PPAR
- IL
- Tumor Necrosis Factor Receptor
- TNFR
- Extracellular signal regulated kinases
- PKB
- Protein kinase B
- Peroxisome proliferator-activated receptors
- ERK1/2
- H1 receptor
- H3 autoreceptor
- PPARγ
- RORγt
- Th17 differentiation
- acetylcholine
- cholinergic neurotransmission
- histamine receptor
- histamine release
- Inhibitor
- inhibitor
- inhibit